US Only Archives - Page 2 of 3 - European Medical Journal

ACR 2025: GLP-1 Drugs Reduce Rheumatoid Arthritis Flares

ACR 2025: GLP-1 Drugs Reduce Rheumatoid Arthritis Flares

New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid arthritis flares and inflammation.

ACR 2025: Maternal Blood Markers Could Predict Fetal Heart Block

New research presented at ACR 2025 reveals IL-6 and CCL3 as predictive markers of fetal heart block in anti-Ro–positive pregnancies, paving the way for early detection and prevention.

Shifting the Silence in Pulmonary Fibrosis

Pulmonary fibrosis remains one of the most challenging respiratory diseases – often underdiagnosed, undertreated, and misunderstood…

Pulmonologists' Pocket Guide to Non-Small Cell Lung Cancer Care

From the first suspicion of lung cancer through diagnosis, treatment, and long-term management, pulmonologists remain central to the…

Paradigm Shift in ESR1 Testing: Spot Resistance Earlier

Explore ESR1 mutations in HR-positive breast cancer and how early ctDNA monitoring may help delay endocrine resistance…

Zongertinib: A New Option In HER2-Mutant NSCLC

HER2 (ERBB2)-mutant metastatic non-small cell lung cancer (NSCLC) remains a clinical challenge, with limited treatment options and…

Interview: Tina Tan

My mission and vision for IDSA during my tenure as President have been to continue advocating strongly for the society’s strategic…

The Role of IL-5 in Inflammatory Diseases

This infographic explores the expanding understanding of interleukin-5 (IL-5) in inflammatory diseases, highlighting that IL-5 impacts…

24 Jun 2025

Explore the Mechanism of Action and 5-Year Data of Deucravacitinib

Learn about the mechanism of action and latest clinical safety and efficacy data of deucravacitinib.

Emerging Strategies for Stage II Seminoma Seek to Minimize Harm Without Sacrificing Cure

Efforts to optimize treatment for Stage II testicular seminoma are intensifying, as new approaches aim to reduce long-term toxicity while preserving the high cure rates associated with standard therapies.